Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $41.89 USD
Change Today +0.73 / 1.77%
Volume 10.4M
ABT On Other Exchanges
New York
SIX Swiss Ex
Sao Paulo
As of 4:15 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/15 - $51.74
52 Week Low
09/28/15 - $39.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABBOTT LABORATORIES (ABT)

abbott laboratories (ABT) Details

Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices to treat vascular diseases. Abbott Laboratories also offers blood, continuous, and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes under the FreeStyle brand; and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. The company serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. It has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

77,000 Employees
Last Reported Date: 02/27/15
Founded in 1888

abbott laboratories (ABT) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $2.0M
Executive Vice President of Ventures
Total Annual Compensation: $696.8K
Executive Vice President of Diagnostic Produc...
Total Annual Compensation: $690.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $650.0K
Executive Vice President of Finance & Adminis...
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2014.

abbott laboratories (ABT) Key Developments

Abbott Declares Quarterly Common Dividend, Payable November 15, 2015

The board of directors of Abbott declared a quarterly common dividend of 24 cents per share. The cash dividend is payable November 15, 2015, to shareholders of record at the close of business on October 15, 2015.

Abbott Announces Positive Results of its Naturally Dissolving Stent from ABSORB Japan Study

Abbott announced positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ®, Abbott's, permanent drug eluting stent. The trial was conducted in 38 sites in Japan and enrolled 400 people with coronary artery disease, the most common form of heart disease. The results will be featured at a late-breaking session at ESC Congress 2015, an annual event of the European Society of Cardiology that brings together cardiologists from around the world, with the goal of reducing the burden of cardiovascular disease. In addition, the data was published simultaneously in the European Heart Journal. Absorb is a first-of-its-kind device that functions like a permanent, metallic stent by opening a blocked artery in the heart, restoring blood flow and providing relief from symptoms of CAD. However, unlike a metallic stent, which permanently restricts vessel movement and limits future treatment options, Absorb is made of a naturally dissolvable material that leaves behind a restored vessel free of a permanent implant, with the potential to flex, pulse and dilate in response to various demands on the heart, based on people's lifestyle and activities. Key findings of ABSORB Japan include: A primary endpoint of target lesion failure (TLF) of 4.2% for Absorb and 3.8% for XIENCE· The major secondary endpoint of angiographic in-segment late lumen loss (LLL), with 95% angiographic follow-up, at 0.13+0.30 mm for Absorb and 0.12+0.32 mm for XIENCE. The rates of stent thrombosis (ST) for Absorb and XIENCE were both 1.5% for definite and probable ST (p=1.0). Rate of repeat procedures was infrequent for both devices at 2.6% with Absorb and 2.3% with XIENCE (p=1.0).

Abbott Laboratories Denies Report About Plans To Buy STJ Stake

Abbott Laboratories (NYSE:ABT) was rumored to be interested in acquiring a stake in St. Jude Medical Inc. (NYSE:STJ) (STJ). Share price of STJ gained to just more than 5%, after reported that Abbott Laboratories denied reports that it is pursuing a $25 billion bid to buy St. Jude Medical. The Financial Times earlier reported that Abbott Laboratories was planning to make a $25 billion bid for STJ, citing people familiar with the matter. The company is preparing an offer but has not yet put it forward, the paper had said.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT:US $41.89 USD +0.73

ABT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,210 GBp +49.00
Danaher Corp $88.51 USD -0.38
Danone SA €57.95 EUR +0.13
Teva Pharmaceutical Industries Ltd $58.96 USD -0.28
Thermo Fisher Scientific Inc $126.52 USD +0.67
View Industry Companies

Industry Analysis


Industry Average

Valuation ABT Industry Range
Price/Earnings 26.1x
Price/Sales 3.0x
Price/Book 2.6x
Price/Cash Flow 11.8x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at